Santhera secures 20 million francs growth funding for Agamree rollout

Santhera Pharmaceuticals (SIX: SANN) today announced new financing agreements with R-Bridge, an affiliate of CBC Group, and certain funds managed by Highbridge Capital Management, respectively, as well as financial results. The company’s shares were down 5.9% at 13.00 francs in early trading.

This 20 million Swiss francs ($25.3 million) financing is comprised of $13 million from a royalty monetization with R-Bridge, on terms that preserve long-term value while providing near-term capital growth. In addition, Highbridge has strengthened its commitment with an additional 10 million francs upsizing of its convertible bond, extending maturity and providing flexibility. Additional details are provided further down in the press release.

As outlined in today’s results, Santhera continues to expand the global reach of Agamree (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD), with over 1,000 patients treated worldwide. In China, partner Sperogenix Therapeutics is seeing increased demand expectations in 2025 and 2026 following their launch into the private-pay market. In the USA, partner Catalyst Pharmaceuticals reported strong first-half 2025 performance with Agamree sales of $49.4 million, driven by accelerated physician adoption and sustained uptake. Demand across Europe continued to remain strong.